MedPath

EARLY-NH study

Not Applicable
Conditions
octurnal hypertension
Registration Number
JPRN-jRCTs031200364
Lead Sponsor
Kario Kazuomi
Brief Summary

The amount of change in nocturnal blood pressure using the brachial sphygmomanometer, which is the primary endpoint, shown a statistically significant decrease in both systolic and diastolic blood pressure. A statistically significant decrease was also shown in home blood pressure early morning and before bedtime, and in consultation room blood pressure. No serious adverse reactions were reported and no new adverse events/adverse reactions requiring confirmation were noted in the safety evaluation.

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
101
Inclusion Criteria

1) Patients aged 20 years or older at informed consent
2) Patients administered ARB or CCB
3) Patients with a nocturnal systolic BP of at least 120 mmHg

Exclusion Criteria

1) Patients diagnosed with secondary hypertension or malignant hypertension
2) Patients with hyperkalemia or serum potassium levels exceeding 5.0 mEq/L
3) Patients with any cerebro-cardiovascular diseases
4) Patients who used prohibited concomitant medications
5) Patients with severely impaired renal function (eGFRcreat < 30 mL/min/1.73 square meter)
6) Patients with seriously impaired hepatic function (e.g., hepatic failure and hepatic cirrhosis)
7) Patients with a life expectancy within 1 year due to some disease
8) Patients with a history of serious drug allergies
9) Pregnant, possibly pregnant, breast-feeding or planning to become pregnant
10) Patients working the night shift at least 3 days a week in a shift-work system
11) Patients deemed otherwise unsuitable for the study by the investigator

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Efficacy Evaluation<br>Change from baseline in nocturnal BP (systolic BP and diastolic BP)
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath